Astellas Homepage | Astellas Innovation Management LLC

News

News / General News

Dec 03, 2019

Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA^® (pembrolizumab) in Patients with Metastatic Urothelial Cancer

News / General News

Dec 03, 2019

Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutics

News / General News

Oct 31, 2019

PANDION AND ASTELLAS ANNOUNCE COLLABORATION TO DELIVER PANCREAS-TARGETED IMMUNOMODULATORS

News / General News

Oct 25, 2019

European Commission Approves Astellas’ XOSPATA™ (gilteritinib) as a Monotherapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation

News / General News

Oct 02, 2019

Astellas Commits Nearly $13 Million to Fund Boston-area Start-Up Innovation in Cell and Gene Therapy - Financial support for LabCentral Incubators builds on Astellas’ $1 Billion+ investment in Boston’s Life Science Community -

News / General News

Sep 30, 2019

Seattle Genetics and Astellas Announce Results from Phase 1 Trial of Investigational Agent Enfortumab Vedotin in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advanced Bladder Cancer